- Parties: The plaintiffs were Aragon Pharmaceuticals Inc., Sloan-Kettering Institute for Cancer Research (ICR), and Janssen Inc. The defendant was Sandoz Canada. 

- Subject Matter: This is a patent infringement action before the Federal Court under the Patented Medicines (Notice of Compliance) Regulations concerning Canadian Patent No. 3,008,345 (the "345 Patent") and Canadian Patent No. 2,875,767 (the "767 Patent"), as well as CSP 900027, relating to the pharmaceutical product ERLEADA (apalutamide) used in the treatment of prostate cancer. Sandoz Canada Inc. has filed an Amended Statement of Defence and Counterclaim denying infringement and seeking declarations that the asserted claims of both patents are invalid, void, and of no force or effect. The case is ongoing.

- Date: The hearing was set on May 19, 2026. 

- Venue: This was a federal case before the Federal Court. 

- Amount: No financial award was specified.